Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions
N Martinez-Cibrian, R Zeiser, JA Perez-Simon - Blood reviews, 2021 - Elsevier
Graft-versus-host disease (GvHD) was first described in 1959, since then major efforts have
been made in order to understand its physiopathology and animal models have played a …
been made in order to understand its physiopathology and animal models have played a …
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
L Tang, Z Huang, H Mei, Y Hu - Signal Transduction and Targeted …, 2023 - nature.com
The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …
understanding of both the mechanisms of immune responsiveness and immune escape …
Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse
T cells are the central drivers of many inflammatory diseases, but the repertoire of tissue-
resident T cells at sites of pathology in human organs remains poorly understood. We …
resident T cells at sites of pathology in human organs remains poorly understood. We …
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial
Background Interleukin 6 mediates graft-versus-host disease (GVHD) in experimental
allogeneic stem-cell transplantation (allogeneic SCT) and represents an attractive …
allogeneic stem-cell transplantation (allogeneic SCT) and represents an attractive …
Immune regulatory cell infusion for graft-versus-host disease prevention and therapy
Current approaches to prevent and treat graft-versus-host disease (GVHD) after stem cell
transplantation rely principally on pharmacological immune suppression. Such approaches …
transplantation rely principally on pharmacological immune suppression. Such approaches …
Cytokines in graft-versus-host disease
AS Henden, GR Hill - The Journal of Immunology, 2015 - journals.aai.org
Graft-versus-host disease (GVHD) is a complication of allogeneic bone marrow
transplantation whereby transplanted naive and marrow-derived T cells damage recipient …
transplantation whereby transplanted naive and marrow-derived T cells damage recipient …
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) was the first successful
therapy for patients with haematological malignancies, predominantly owing to graft-versus …
therapy for patients with haematological malignancies, predominantly owing to graft-versus …
Eomesodermin promotes the development of type 1 regulatory T (TR1) cells
Type 1 regulatory T (TR1) cells are Foxp3− interleukin-10 (IL-10)–producing CD4+ T cells
with potent immunosuppressive properties, but their requirements for lineage development …
with potent immunosuppressive properties, but their requirements for lineage development …
Late endocrine effects of childhood cancer
SR Rose, VE Horne, J Howell, SA Lawson… - Nature Reviews …, 2016 - nature.com
The cure rate for paediatric malignancies is increasing, and most patients who have cancer
during childhood survive and enter adulthood. Surveillance for late endocrine effects after …
during childhood survive and enter adulthood. Surveillance for late endocrine effects after …
GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSCs) are a naturally occurring immune regulatory
population associated with inhibition of ongoing inflammatory responses. In vitro generation …
population associated with inhibition of ongoing inflammatory responses. In vitro generation …